Report: Bioprocessing trends 2018-2023

By Flora Southey contact

- Last updated on GMT

(Image: Getty/denizbayram)
(Image: Getty/denizbayram)

Related tags: CAR-T, Continuous manufacturing

Increased cell and gene therapy production and reduced development timelines are listed among bioprocessing trends predicted over the next five years, says consultant.

According to Mike Ultee of Ulteemit Bioconsulting, the bioprocessing industry should prepare for a number of growing trends in the development and manufacture of biologics. Among the predictions, cited in the CPhI Worldwide Annual Report, are improved productivity of fusion proteins and enzymes, and the rise of continuous bioprocessing.

Chimeric antigen receptor (CAR) T-cell therapy pipelines will continue to advance towards commercialisation, said Ultee.

“In five years’ time, we will have been through a golden period, with game-changing improvements made in upstream, downstream and continuous bioprocessing.

“The market will by then also boast much greater numbers of biosimilars and new applications for cell and gene therapies. The industry is collectively maturing extremely quickly from big pharma and biosimilars to contract development and manufacturing organisations (CDMOs),” ​he added.

Related news

Related products

show more

Manufacturing of hiPSC-Derived Cardiomyocytes

Manufacturing of hiPSC-Derived Cardiomyocytes

Eppendorf for Bioprocess – Solutions that grow with you | 29-Oct-2020 | Application Note

Effective drug discovery and development relies on the availability of predictive preclinical model systems. Technologies based on human induced pluripotent...

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Related suppliers

Follow us

Products

View more

Webinars